SCHEMBL1444302

SCHEMBL1444302

O=C(O)c1[nH]c(-c2ccccc2)c(-c2cccc(Cl)c2F)c1-c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.48
MAP2 P11137 2/20 0.43
MDM2 Q00987 2/20 0.43
KMO O15229 2/20 0.39
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
PIN1 Q13526 3/20 0.38
ALOX15 P16050 2/20 0.37
IDO1 P14902 1/20 0.36
MAPK13 O15264 1/20 0.36
RAF1 P04049 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
CHRM1 P11229 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
CTSA P10619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437660 0.88 SLC6A3 (0.39) GPR35MDM2MAPK14CHRM1GAA
SCHEMBL27879102 0.83 MDM2 (0.41) GPR35MDM2KMOFABP4IDO1
SCHEMBL27879101 0.82 MDM2 (0.39) GPR35MAP2MDM2KMOPIN1
SCHEMBL20568174 0.76 MAP2 (0.49) GPR35MAP2MAPK13RAF1MAPK12
SCHEMBL24744340 0.72 GPR35 (0.48) GPR35MAP2PIN1ALOX15IDO1
SCHEMBL30115783 0.72 GPR35 (0.48) GPR35MAP2PIN1ALOX15IDO1
SCHEMBL11242216 0.71 GPR35 (0.58) GPR35MAP2KMOPIN1IDO1
SCHEMBL20568071 0.68 MAP2 (0.49) GPR35MAP2FABP3FABP4PIN1
SCHEMBL11538110 0.67 MAP2 (0.58) GPR35MAP2FABP3FABP4
SCHEMBL11547898 0.66 MAP2 (0.54) GPR35MAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574785-A Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators NOVARTIS AG 2012-07-11 CN disclosed
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 GPR35 4002/4885MAP2 1458/4885MDM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.